The production of congenital malformations using tissue antisera. X. Effectiveness of kidney antigens treated with neuraminidase or trypsin.
D000042:Absorption; D000818:Animals; D000906:Antibodies / Q000032:analysis; D000937:Antigen-Antibody Reactions; D000941:Antigens / Q000009:adverse effects*; D000013:Congenital Abnormalities / Q000209:etiology*; D005314:Embryonic and Fetal Development; D005260:Female; D005313:Fetal Death; D005315:Fetal Diseases / Q000276:immunology; D005455:Fluorescent Antibody Technique; D006130:Growth Disorders; D007106:Immune Sera / Q000008:administration & dosage / Q000009:adverse effects*; D005779:Immunodiffusion; D007668:Kidney / Q000276:immunology*; D008431:Maternal-Fetal Exchange; D008856:Microscopy, Fluorescence; D009439:Neuraminidase / Q000494:pharmacology*; D011233:Precipitin Tests; D011247:Pregnancy; D011507:Proteinuria / Q000276:immunology; D011817:Rabbits / Q000276:immunology; D051381:Rats; D014357:Trypsin / Q000494:pharmacology*; D014817:Vitelline Membrane / Q000276:immunology; D005719:gamma-Globulins / Q000032:analysis
D000906:Antibodies; D000941:Antigens; D007106:Immune Sera; D005719:gamma-Globulins; D009439:Neuraminidase; D014357:Trypsin